Neurology

Immune-related adverse events

Questions discussed in this category

How do you manage immunotherapy-induced myasthenia gravis?

Are there any risk factors for IO induced rhabdomyolysis and how do you approach and manage it?

Would you give checkpoint inhibitor therapy to a cancer patient with known dermatomyositis given the association of checkpoint inhibitor associated myocarditis, myasthenia gravis, and myositis?

6 Answers available

Is IL-6 inhibition an option in patients who are going to be rechallenged with checkpoint inhibitors after previously developing ICI-mediated temporal arteritis?

Would the checkpoint inhibitor still work if blocking only that portion of the inflammatory cascade as opposed to more global blockade with steroids?

2 Answers available

What is your preferred steroid sparing therapy in a patient experiencing a severe checkpoint inhibitor toxicity and not responding to high dose IV steroids?

2 Answers available

How would you approach the treatment of checkpoint-inhibitor-mediated temporal arteritis?

Is there role for IVIG? Would you alter the dose or time course of steroid therapy?

2 Answers available

What are your recommendations for a patient with metastatic non-mutated lung adenocarcinoma who previously had headaches responsive to prednisone but with negative temporal artery biopsy for GCA?

For medical oncologists, would you offer a PD-1/L1 inhibitor? For other subspecialties, how would you counsel the oncologist regarding the risk of usi...

1 Answer available

What features help distinguish thyroid myopathy from immune checkpoint inhibitor-associated myopathy?

1 Answer available

How would you approach evaluation and treatment of a patient on pembrolizumab therapy who presents with symmetric, proximal, upper extremity and lower extremity painful weakness without an elevated CK?

1 Answer available

Papers discussed in this category

Arthritis Rheumatol, 2021 Apr 01

Inflammatory Myositis in Cancer Patients Receiving Immune Checkpoint Inhibitors.

Eur J Cancer, 2021 Sep 15

Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy.

Thorac Cancer, 2020 Feb 11

The role of IL-6 in immunotherapy of non-small cell lung cancer (NSCLC) with immune-related adverse events (irAEs).

Journal of immunotherapy (Hagerstown, Md. : 1997), 2018-05

PD-1 Inhibitor-associated Myopathies: Emerging Immune-mediated Myopathies.

Neurology, 2019 Mar 08

Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies: Systematic review.

Front Immunol, 2022 Aug 22

Neuromuscular junction dysfunctions due to immune checkpoint inhibitors therapy: An analysis of FAERS data in the past 15 years.

Cureus, 2022 Oct 24

Myasthenia Gravis in the Setting of Immune Checkpoint Inhibitor Therapy: Practical Considerations and Opinion-Based Approach to Acute Management.

Neurology

Immune-related adverse events

Questions discussed in this category

Papers discussed in this category

Related Topics in Neurology